Patents by Inventor Adekunle Odunsi

Adekunle Odunsi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11020431
    Abstract: Provided are recombinant polynucleotides, including expression vectors encoding an alpha chain and/or a beta chain of a TCR having amino acid sequences from any of novel the AL, KQ, PP, 19305CD8, BB, KB, ST, JD, 19305DP, PB-P, PB-T, and PB 13.2 T Cell Receptors (TCRs) that are embodiments of the invention. Cells comprising the polynucleotides are provided, as are libraries of the recombinant polynucleotides and expression vectors. Methods are provided and involve administering to an individual modified human T cells that express a novel recombinant TCR. The methods are for prophylaxis and/or therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer includes cancer cells which express NY-ESO-1 and/or its highly homologous LAGE-1 antigen.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 1, 2021
    Assignee: Health Research, Inc.
    Inventors: Adekunle Odunsi, Takemasa Tsuji, Junko Matsuzaki
  • Publication number: 20190275081
    Abstract: Provided are recombinant polynucleotides, including expression vectors encoding an alpha chain and/or a beta chain of a TCR having amino acid sequences from any of novel the AL, KQ, PP, 19305CD8, BB, KB, ST, JD, 19305DP, PB-P, PB-T, and PB 13.2 T Cell Receptors (TCRs) that are embodiments of the invention. Cells comprising the polynucleotides are provided, as are libraries of the recombinant polynucleotides and expression vectors. Methods are provided and involve administering to an individual modified human T cells that express a novel recombinant TCR. The methods are for prophylaxis and/or therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer includes cancer cells which express NY-ESO-1 and/or its highly homologous LAGE-1 antigen.
    Type: Application
    Filed: January 6, 2017
    Publication date: September 12, 2019
    Inventors: Adekunle ODUNSI, Takemasa TSUJI, Junko MATSUZAKI
  • Publication number: 20140156573
    Abstract: A method for generating a model for epithelial ovarian cancer is presented, comprising the steps of obtaining a mass spectrum for each of a plurality of samples, segmenting each of the mass spectra into “bins,” and determining a plurality of relationships between two or more bins. One are more statistically significant factors are identified according to the determined plurality of relationships, and a predictive model is generated as a function of the one or more identified factors. A method of the present invention may further comprise the step of obtaining one or more nuclear magnetic resonance spectra of each of the samples, which are segmented into a plurality of bins. Combinations of mass spectra and NMR spectra may be used to determine the plurality of relationships. In other embodiments, methods for identifying the presence of EOC indicated by a biological sample of an individual are presented.
    Type: Application
    Filed: July 27, 2012
    Publication date: June 5, 2014
    Applicant: The Research Foundation of State University of New York
    Inventors: Thomas Szyperski, Christopher Andrews, Dinesh K. Sukumaran, Adekunle Odunsi